An open label, phase 2 study of ibrutinib in combination with rituximab and lenalidomide in previously untreated subjects with follicular lymphoma and marginal zone lymphoma
The goal of this clinical research study is to learn if adding Imbruvica (ibrutinib) to Rituxan (rituximab) and Revlimid (lenalidomide) can help to control previously untreated follicular lymphoma (FL) and marginal zone lymphoma.
Treatment Location: N/A
IRB Review and Approval Date: 04/11/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: